GlassScriptPhysician profile
Mary M Meyer
NPI 1417078239
$1,187.04
in general payments reported to CMS, 2019-2025
14 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $219 · 2023: $324 · 2024: $126 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.09 | 2021-2025 | |
| Hologic Sales and Service, LLC | $191.42 | 2022-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Organon LLC | $70.57 | 2021-2024 | Nexplanon |
| Shield Therapeutics INC | $61.46 | 2025 | |
| Exeltis, USA INC. | $44.83 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $44.52 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.97 | 2021-2022 | |
| Millicent US INC | $22.36 | 2024 | Intrarosa, Femring |
| Agile Therapeutics, INC. | $20.63 | 2021 | |
| Myovant Sciences INC. | $19.24 | 2022 | |
| Merck Sharp & Dohme LLC | $17.92 | 2021 | |
| Therapeuticsmd, INC. | $16.41 | 2021 | |
| Avion Pharmaceuticals | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.